Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Total Liabilities for 10 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 29.33% to $1.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Dec 2025, up 29.33% year-over-year, with the annual reading at $1.6 billion for FY2025, 29.33% up from the prior year.
  • Total Liabilities for Q4 2025 was $1.6 billion at Ultragenyx Pharmaceutical, up from $1.2 billion in the prior quarter.
  • The five-year high for Total Liabilities was $1.6 billion in Q4 2025, with the low at $540.3 million in Q2 2021.
  • Average Total Liabilities over 5 years is $1.0 billion, with a median of $1.2 billion recorded in 2023.
  • Peak annual rise in Total Liabilities hit 177.67% in 2021, while the deepest fall reached 12.95% in 2021.
  • Over 5 years, Total Liabilities stood at $599.8 million in 2021, then skyrocketed by 98.88% to $1.2 billion in 2022, then increased by 1.9% to $1.2 billion in 2023, then increased by 2.09% to $1.2 billion in 2024, then grew by 29.33% to $1.6 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $1.6 billion, $1.2 billion, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.